Carisma Therapeutics (NASDAQ:CARM) Insider Michael Klichinsky Sells 200,000 Shares

Carisma Therapeutics Inc. (NASDAQ:CARM) insider Michael Klichinsky sold 200,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $0.25, for a total transaction of $50,000.00. Following the completion of the transaction, the insider directly owned 119,347 shares of the company’s stock, valued at approximately $29,836.75. This trade represents a 62.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Michael Klichinsky also recently made the following trade(s):

• On Friday, October 3rd, Michael Klichinsky sold 119,347 shares of Carisma Therapeutics stock. The stock was sold at an average price of $0.26, for a total transaction of $31,030.22.
• On Wednesday, October 1st, Michael Klichinsky sold 165,000 shares of Carisma Therapeutics stock. The stock was sold at an average price of $0.26, for a total transaction of $42,900.00.

Carisma Therapeutics Trading Down 3.4%

CARM opened at $0.26 on Friday. The company has a 50 day moving average of $0.30 and a 200 day moving average of $0.30. The company has a market cap of $10.90 million, a PE ratio of -0.17 and a beta of 2.06. Carisma Therapeutics Inc. has a 12 month low of $0.14 and a 12 month high of $1.27.

Hedge Funds Weigh In On Carisma Therapeutics

An institutional investor recently bought a new position in Carisma Therapeutics stock. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Carisma Therapeutics Inc. (NASDAQ:CARM) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 200,000 shares of the company’s stock, valued at approximately $62,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.48% of Carisma Therapeutics at the end of the most recent reporting period. Institutional investors own 44.27% of the company’s stock.

Analyst Upgrades and Downgrades

CARM has been the subject of several analyst reports. D. Boral Capital reaffirmed a “buy” rating and issued a $1.00 price objective on shares of Carisma Therapeutics in a report on Friday, August 8th. Evercore ISI raised shares of Carisma Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 15th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Carisma Therapeutics in a research note on Saturday, September 27th. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1.93.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.